290 likes | 419 Views
CONNECTICUT PUBLIC HEALTH ASSOCIATION HEALTH EDUCATION COMMITTEE 6-12-2013. DEBBYE ROSEN, BSN, MS ADULT IMMUNIZATION COORDINATOR CT DEPARTMENT OF PUBLIC HEALTH 860-509-7729 debbye.rosen@ct.gov. REVIEW INFLUENZA SURVEILLANCE FOR 2012-2013, CT AND NATIONAL
E N D
CONNECTICUT PUBLIC HEALTH ASSOCIATIONHEALTH EDUCATION COMMITTEE6-12-2013 DEBBYE ROSEN, BSN, MS ADULT IMMUNIZATION COORDINATOR CT DEPARTMENT OF PUBLIC HEALTH 860-509-7729 debbye.rosen@ct.gov
REVIEW INFLUENZA SURVEILLANCE FOR 2012-2013, CT AND NATIONAL • REVIEW INFLUENZA VACCINATION DATA, NATIONAL 2012-2013 • INFLUENZA VACCINE RECOMMENDATIONS 2013-2014 • INFLUENZA VACCINE PRODUCTS 2013-2014 • UPDATE H7N9 – IS THIS THE “NEW” PANDEMIC
OBJECTIVES • DESCRIBE THE INFLUENZA SURVEILLANCE PROCESS • LIST THE 2012-2013 INFLUENZA VACCINATION RECOMMENDATIONS • LIST THE KEY POINTS TO FOLLOW IN THE H7N9 INFLUENZA • OUTBREAK
BURDEN OF DISEASE, U.S. ADULTS • INFLUENZA • 3,000 to 49,000 total related deaths per year • • ~90% among adults 65 years and older • Invasive pneumococcal disease (IPD)1 • 39,750 total cases and 4,000 total deaths in 2010 • • 86% of IPD and nearly all IPD deaths among adults • Pertussis • 41,880 total reported cases 2012 • • ~9,000 among adults • Hepatitis B • 3,350 acute cases reported 2010 • • 35,000 estimated • Zoster • about 1 million cases of zoster annually in the U.S. • 1.CDC. Active Bacterial Core Surveillance. http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf. • 2.CDC. Estimates of deaths associated with seasonal influenza – United States, 1976-2007. MMWR. 2010;59(33):1057-1062. • 3.CDC. Notifiable Diseases and Mortality Tables. MMWR 2013. 61(51&52): ND-719 – ND 732. • 4.CDC. Viral Hepatitis Surveillance United States, 2010. National Center for HIV/AIDS, Viral Hepatitis, STD& TB Prevention/Division of Viral Hepatitis. • 5.CDC. Prevention of Herpes Zoster. MMWR 2008. 57(RR-5): 1-30.
INFLUENZA SURVEILLANCE • NATIONAL DATA • CULTURE CONFIRMED FROM STATES • INFLUENZA LIKE ILLNESS • DEATHS FROM PNEUMONIA AND INFLUENZA-CITIES • DEATHS IN CHILDREN <5 YRS • CULTURE POSITIVE HOSPITALIZED PATIENTS • CONNECTICUT • EMERGENCY ROOM VISITS
DEATHS , INFLUENZA RELATED CT 2012-2013 • TOTAL= 37 • 89% >65 YRS, 11% 55-64 YRS • NO DEATHS < 5 YRS.
MODERATE TO SEVERE SEASON • EARLY DISEASE • ELDERLY SEVERELY IMPACTED
MEASURING INFLUENZA VACCINATIONS • VACCINATION RATES • BRFSS (ADULTS) • NATIONAL IMMUNIZATION SURVEY (CHILDREN) • NHIS (ADULTS) • NATIONAL FLU SURVEY (ADULTS,HCP, PREGNANT) • VACCINE EFFECTIVENESS
VACCINE EFFECTIVENESS • INFLUENZA A & B VIRUS ASSOCIATED WITH MEDICALLY ATTENDED ACUTE RESPIRATORY ILLNESS 56% • 47% AGAINST INFLUENZA A (H3N2) • 67 % AGAINST INFLEUNZA B • 23% (9%) AGAINST INFLUENZA A (H3N2) PEOPLE > 65 YRS
WHO SHOULD GET VACCINATED IN 2013-2014 • > 6 MONTHS • WHO SHOULD NOT GET VACCINATED • SEVERE REACTION TO PREVIOUS FLU VACCINE • GUILLAIN-BARRÉ • < 6 MONTHS • MODERATE SEVERE ILLNESS • EGG ALLERGY ????????
FLU VACCINE PRODUCTS 2013-2014 • 10 VACCINE PRODUCTS • 6 MANUFACTURERS • NEW PRODUCTS • LIV4 • IIV4 • CELL CULTURE (ccIIV3) • RECOMBINANT HEMAGGLUTIN INFLUENZA VACCINE (RIV3 FLUBLOK)
H7N9 ????????THE NEXT PANDEMIC • > 130 CASES IDENTIFIED IN 10 CHINA PROVINCES • NO U.S. CASES • NO SUSTAINED HUMAN TO HUMAN TRANSMISSION • TESTING KITS ARE AVAILABLE • CANDIDATE VACCINE DEVELOPED • CLINICAL TRIALS • # OF DOSES NEEDED • ADJUVANT TO BOOST RESPONSE
RESOURCES • CENTERS FOR DISEASE CONTROL AND PREVENTION www.cdc.gov/flu • DEPARTMENT OF PUBLIC HEALTH IMMUNIZATION PROGRAM • www.ct.gov/dph/immunizations • IMMUNIZATION ACTION COALITIION • www.immunize.org
DEBBYE ROSEN, BSN, MS ADULT IMMUNIZATION COORDINATOR CT DEPARTMENT OF PUBLIC HEALTH 860-509-7729 debbye.rosen@ct.gov ????????????????????????????